Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 14/20 | 0.67 |
| ▸ | ACE | P12821 | 8/20 | 0.67 |
| ▸ | MMEL1 | Q495T6 | 4/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11918359 | 1.00 | MME (0.67) | MMEACEMMEL1TAAR1GPR34 | |
| SCHEMBL14919078 | 0.86 | MME (0.65) | MMEACEMMEL1TAAR1 | |
| SCHEMBL14932467 | 0.86 | MME (0.65) | MMEACEMMEL1TAAR1 | |
| SCHEMBL14890701 | 0.86 | MME (0.65) | MMEACEMMEL1TAAR1 | |
| SCHEMBL15354945 | 0.85 | MME (0.57) | MMEACEMMEL1TAAR1MAOB | |
| SCHEMBL3353929 | 0.85 | MME (0.60) | MMEACE | |
| SCHEMBL1768194 | 0.84 | GPR34 (0.56) | MMEACEMMEL1GPR34 | |
| SCHEMBL1768190 | 0.84 | GPR34 (0.56) | MMEACEMMEL1GPR34 | |
| SCHEMBL8592637 | 0.82 | KDM6B (0.56) | MMEACE | |
| SCHEMBL3347144 | 0.82 | KDM6B (0.56) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735561-B1 | Substituted carbamoylmethoxyacetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8877786-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877786-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| EP-2735561-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | Novartis AG (CH) | 2014-05-28 | — | — | EP | disclosed |
| US-20140088165-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8377978-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2013-02-19 | — | — | US | disclosed |
| US-20120202862-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8222286-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-8222286-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| WO-2011061271-A1 | SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088165-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | MME 1/4885ACE 4/4885MMEL1 485/4885 |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885ACE 92/4885MMEL1 118/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885ACE 92/4885MMEL1 118/4885 |
| US-20120202862-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | MME 1/4885ACE 4/4885MMEL1 485/4885 |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | MME, REN, AGTR1 | MME 1/4885ACE 4/4885MMEL1 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.